- Conditions
- COVID-19
- Interventions
- Sarilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 62
- States / cities
- Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Cancer
- Interventions
- Sodium Cridanimod, progestin therapy
- Drug
- Lead sponsor
- Xenetic Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 25
- States / cities
- Burbank, California • Irvine, California • Los Angeles, California + 22 more
- Conditions
- Dental Caries
- Interventions
- UDMA-K18 smooth surface sealant
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 89 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- Tucatinib in Combination with Palbociclib and Letrozole
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Advanced Solid Tumors
- Interventions
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more
- Conditions
- Low Bone Mass, Osteoporosis, Postmenopausal
- Interventions
- DHEA, Placebo, Exercise
- Other · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years to 85 Years · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Neuroblastoma
- Interventions
- Sorafenib, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Twin to Twin Transfusion Syndrome, Pregnancy Complications, Multiple Gestation; Maternal Care
- Interventions
- Not listed
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- San Diego, California • Aurora, Colorado • Annapolis, Maryland + 5 more
- Conditions
- Osteoporosis, Circadian Rhythm Sleep Disorder, Shift Work Type
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, erlotinib hydrochloride
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 153
- States / cities
- Antioch, California • Berkeley, California • Burlingame, California + 109 more
- Conditions
- Breast Neoplasm
- Interventions
- Sagopilone (ZK 219477)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 18 more
- Conditions
- Vision Disorders
- Interventions
- Welch-Allyn Spot Vision Screener
- Diagnostic Test
- Lead sponsor
- Children's Hospital Colorado
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Type 1 Diabetes
- Interventions
- Bromocriptine, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pneumonia, Bacterial
- Interventions
- ME1100 inhalation solution
- Drug
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Martinez, California • Sacramento, California • San Diego, California + 11 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
- Interventions
- Observational Protocol
- Other
- Lead sponsor
- European Foundation for Study of Chronic Liver Failure
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3,000 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
- Conditions
- Type 1 Diabetes (T1D), Sleep Health
- Interventions
- Sleep Health and Circadian Timing Intervention
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 14 Years to 19 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 201
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 129 more
- Conditions
- Ewing Sarcoma, Colorectal Adenocarcinoma
- Interventions
- INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
- Conditions
- Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative
- Interventions
- Screening Mammography, Biospecimen Collection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 514
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Glendale, Arizona + 341 more
- Conditions
- Epilepsy
- Interventions
- observation of VNS stimulation effects
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Questionnaire Administration, Study of Socioeconomic and Demographic Variables
- Behavioral · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 105 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Dapsone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Month to 12 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 29 more